Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

Considering exosome stem cell injections for hair loss alongside minoxidil and finasteride. Some suggest trying dutasteride first due to its proven effectiveness.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Minoxidil and dutasteride are discussed as treatments for hair loss, with some users sharing positive experiences and others noting side effects. The effectiveness of these treatments varies, and some users consider additional options like finasteride and topical sprays.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.

A 19-year-old started Dutasteride at 17 to combat aggressive hair thinning, which halted his facial hair development despite having strong beard genetics. He also used oral and topical Minoxidil without success for facial hair, and the discussion highlights the impact of DHT blockers on beard growth.

The conversation is about a user's hair regrowth progress using topical minoxidil, with plans to start finasteride. The user also takes Vitamin D and washes their hair 2-3 times a week.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.

Exosome treatment for hair loss is viewed skeptically, with one person calling it a scam. Another suggests sticking with finasteride and minoxidil instead.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

Applying minoxidil with long hair can be challenging due to its oily appearance, but users suggest methods like using a topical applicator, parting hair, or applying to damp hair. Some prefer oral minoxidil for ease, while others use foam or adjust application techniques to target the scalp effectively.

People are discussing early results of the grey market hair loss treatment PP405. They mention previous attempts with jxl069 and interest in PP30.

Dutasteride and minoxidil changed the user's hair texture, making it stronger, thicker, and curlier. The user takes 0.5mg dutasteride and 2.5mg minoxidil orally.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.